Shares of Enochian Biosciences Inc. (NASDAQ:ENOB) traded at a new 52-week high today of $6.17. Approximately 15.1 million shares have changed hands today, as compared to an average 30-day volume of 127,000 shares.
Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in identifying, developing, manufacturing, and commercializing gene therapies. The company develops cures and providing prevention for infectious diseases and cancer. It is also engaged in developing HIV preventative vaccine and cures and Cellular immune-oncology products.
Based on a current price of $6.02, Enochian Biosciences Inc. is currently 37.3% above its average consensus analyst price target of $3.77.
In the past 52 weeks, shares of Enochian Biosciences Inc. have traded between a low of $2.60 and a high of $6.17 and is now at $6.02, which is 132% above that low price.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com